ArticleJournal of family medicine and primary care2021
APRI and FIB-4 performance to assess liver fibrosis against predefined Fibroscan values in chronic hepatitis C virus infection.
Article in Journal of family medicine and primary care, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 39 citations in OpenAlex.
- Are there any non-invasive methods to predict liver fibrosis in children infected by hepatitis C virus rather than liver biopsy?Clinical and experimental hepatology · 2026Article
- Prognostic value of the fibrosis-4 index for predicting in-hospital mortality in sepsis patients: evidence from MIMIC-IV and eICU databases.Scientific reports · 2026Article
- Noninvasive Assessment of Hepatic Steatosis in Living Liver Donors.Diagnostics (Basel, Switzerland) · 2026Article
- Development of a hybrid deep learning-based framework for liver fibrosis classification using ultrasound images.iLIVER · 2026Article
- APRI and FIB-4 indices as systemic fibrosis markers in proliferative vitreoretinopathy.BMC ophthalmology · 2026Article
- Evaluation of Fibrosis-4 Index, nonalcoholic fatty liver disease fibrosis score, and aspartate aminotransferase-to-platelet ratio index as noninvasive indicators of fibrosis in patients with nonalcoholic fatty liver disease.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2026Article
- Role of mac-2 binding protein glycosylation isomer in predicting fibrosis in patients with metabolic dysfunction-associated steatotic liver disease.World journal of hepatology · 2025Article
- Validation of albumin platelet product as a non-invasive fibrosis staging tool in patients with chronic HCV-related liver disease.Scientific reports · 2025Article
- Hepatitis C Virus Cascade of Care After the Introduction of Direct-Acting Antiviral Medications in Suriname.Cureus · 2025Article
- Extracellular vesicles derived microRNAs as non-invasive markers of liver fibrosis in chronically infected HCV patients: a pilot study.Non-coding RNA research · 2025Article
- The role of the AST-to-platelet ratio index (APRI) score on outcomes following robotic minor, technically major, & major hepatectomy for liver tumors.Journal of robotic surgery · 2025Article
- Associations among serum levels of MMP-1, MMP-2, and METAVIR fibrosis score in patients with nonalcoholic fatty liver disease.Gastroenterology and hepatology from bed to bench · 2025Article
- Aspartate Aminotransferase to Platelet Ratio Index (APRI), Göteborg University Cirrhosis Index (GUCI), and Fibrosis 4 Score (FIB-4) proved to be the optimal biomarkers for the assessment of liver fibrosis in patients chronically infected with hepatitis C virus in Brazil.Revista da Associacao Medica Brasileira (1992) · 2025Article
- A structured list of laboratory tests for screening the possible causes of small fiber neuropathy in clinical practice.Frontiers in neurology · 2025Review
- Comparison of different noninvasive scores for assessing hepatic fibrosis in a cohort of chronic hepatitis C patients.Scientific reports · 2024Article
- Development of a diagnostic support system for the fibrosis of nonalcoholic fatty liver disease using artificial intelligence and deep learning.The Kaohsiung journal of medical sciences · 2024Article
- Risk Factors for Progressive Fibrosis and Cirrhosis in Patients With Chronic Hepatitis C in India.Cureus · 2024Article
- Hepatocellular Carcinoma: The Role of Surgery in Liver Cirrhosis.Visceral medicine · 2024Review
- The impact of drug-eluting bead (vs. conventional) transarterial chemoembolization on hepatic fibrosis in treating intermediate or advanced hepatocellular carcinoma.Cancer biology & therapy · 2023Article
- The Use of Noninvasive Scores in Predicting NAFLD Progression After Bariatric Surgery.Obesity surgery · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUNDS AND
aimsChronic hepatitis C (CHC) infection can leads to chronic liver disease, fibrosis, then cirrhosis, and, finally, hepatocellular carcinoma (HCC); moreover, it is the most common indication for liver transplantation. Liver biopsy is still the gold standard method for the staging of liver fibrosis as it is an invasive procedure with complications. There are some noninvasive methods such as fibroscan that are now the investigation of choice; FIB-4 and aminotransferase to platelet ratio index (APRI) are other noninvasive tools to assess liver fibrosis by using aspartate aminotransferase (AST), alanine aminotransferase (ALT), platelet count, and age. This study aims to evaluate the efficacy and performance of FIB-4 and APRI against fibroscan in patients infected with the hepatitis C virus.
methodIt is a cross-sectional study that was conducted in a tertiary health care center in Uttar Pradesh, India, from January 2017 to January 2020. Fibroscan was done for all patients. A blood sample was used to determine AST, ALT, and platelet count. FIB-4 and APRI were calculated from laboratory data.
result187 of the 487 patients in the study have F0-F1 fibrosis, 69 have F2, 53 have F3 fibrosis, and 178 have cirrhosis. Based on receiver operating characteristic (ROC) analysis, single optimum cut-offs for diagnosing significant fibrosis and cirrhosis were 1.2 for APRI and 2.25 for FIB-4.
conclusionsCompared with Fibroscan, APRI and FIB-4 showed good performance in detecting the patients without liver fibrosis as well as satisfactory performance in detecting significant fibrosis. These scores should be used in combination with other noninvasive scores for an accurate assessment of liver fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.